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including thrombocytopenia, hemolytic anemia, and AKI with glomerular thrombotic microangiopathy. There were no significant increases in soluble terminal complement complex (C5b-9) levels after challenge with lethal Stx1 (n=6) or Stx2 (n=5) in plasma samples from T0 to euthanasia at 49.5-128 hrs post-challenge. D-dimer and cell injury markers (HMGB1, histones) confirmed coagulopathy and cell injury. Thus, complement activation is not required for the development of thrombotic microangiopathy and HUS induced by EHEC Shiga toxins in these pre-clinical models, and benefits or risks of complement inhibition should be studied further for this infection.
Introduction
Shiga toxin-producing enterohemorrhagic Escherichia coli (EHEC) is an emerging foodand water-borne pathogen. 1 The E.coli O157:H7 is the most common strain and its ribosome inactivating Shiga toxins (Stx1, Stx2) injure receptor-bearing endothelial cells, particularly in renal glomeruli. Hemolytic uremic syndrome (HUS) is a clinically important complication in 5-15% of these patients, characterized by hemolytic anemia, thrombocytopenia and thrombotic microangiopathy, often resulting in severe acute kidney injury necessitating dialysis. Antibiotics increase HUS risk, 2 and this pathogen is the leading cause of acute renal failure in otherwise healthy US children.
The clinical presentation of EHEC-HUS overlaps that of atypical HUS (aHUS), a rare disease induced by genetic abnormalities resulting in unchecked alternative complement pathway activation. 3 Immuno-inhibition of complement C5 activation in aHUS patients with Eculizumab (Solaris®) reduces levels of inflammatory complement mediators and the terminal complement complex (TCC, soluble C5b-9), and normalizes clinical indicators. 4 The clinical similarity of these syndromes has led to considerable discussion in the EHEC field about whether Stx activities activate complement, which then becomes a major driving force for HUS development.
In vitro and murine data support complement activation, [5] [6] [7] but in vitro data arise from toxin challenges ~500,000 times higher than the 5-20 pg/ml Stx levels observed in infected children. We quantified D-dimer as a marker of fibrinolysis, as well as cell injury markers HMGB1 and histones.
Methods

Baboon Samples
Methods and characterization of the nonhuman primate (juvenile Papio baboons, 4~6kg) challenges with lethal Stx1 (100ng/kg) or Stx2 (50ng/kg) are described. 10, 11 All animals developed HUS with thrombotic microangiopathy and progressive loss of renal function.
Animal studies were performed under the oversight of the regulatory IACUC and IBC of the Boston University School of Medicine.
ELISA Assays
Baboon HMGB1was quantified using HMGB1 ELISA (IBL International, Hamburg, Germany) and histones by using Cell Death Detection ELISA plus (Roche Inc., Indianapolis, IN). Stored EDTA-plasma from bacteremic baboons challenged intravenously with sub-lethal 5x10 9 CFU/kg E. coli B7 O86a:K61 (SLEC; not toxigenic) 13 or lethal 3x10 9 CFU/kg Bacillus anthracis Sterne strain 34F2 (vaccine strain) 14 were positive controls. Data were analyzed for differences between groups using Student's T-test, assuming equal variance.
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Results and Discussion
Bacteremia is rare in patients with EHEC infection and the Shiga toxins are widely acknowledged as the primary mediators of organ injury. 15, 16 Our nonhuman primate models are the only animal models to date that present with full spectrum HUS induced by only Stx challenge. Some differences are observed between the toxins with respect to timing and inflammation 10 or renal pathology 12 , but the classic triad of hemolytic anemia, thrombocytopenia and thrombotic microangiopathy with acute kidney injury are shared responses after Stx1 or Stx2. Given the success of complement inhibition in aHUS patients, we measured soluble TCC in our Stx-HUS models to determine whether complement is activated and, if so, when. There were no significant increases in soluble TCC levels in animals after lethal challenge with Stx1 ( Fig 1A; n=6) or Stx2 (Fig 1B; n=5) For
